Back to List View Graph View

Camptothecin

Camptothecin (CPT) is a cytotoxic quinoline alkaloid of the monoterpene indole class, first isolated from the bark and wood of Camptotheca acuminata, a tree native to southern China.

Where the papers sit

15 papers from the last 6 months study camptothecin directly · updated from PubMed 12 Oct 2026

Study type 0 clinical trials · 15 preclinical

Themes one subject · 1 new direction

Those 15 are all about one subject.

  • Targeted Camptothecin Delivery

    Controlled-release nanomedicines and prodrugs are moving camptothecin toward tumor-selective, externally or biomarker-activated therapy. pH, ROS, redox, HOCl and enzyme triggers recur alongside light-controlled release and fluorescence or chemiluminescence reporting. Combination designs pair camptothecin with cabazitaxel, niraparib, sonodynamic or photodynamic therapy, and immunotherapy, aiming to improve efficacy and overcome resistance. ADC linker-payloads and improved biosynthesis broaden the path from drug production to precise delivery.

    15 papers

NEW DIRECTION

Camptothecin is treated as a biosynthetic production target rather than a therapeutic payload

The Camptotheca acuminata biosynthesis study examines camptothecin production in transgenic plants 42138768May. Whereas the other camptothecin papers use it as a cytotoxic agent to be released, delivered, or compared with, this study treats camptothecin as a natural product whose supply can be increased by engineering metabolism: heterologous CrLAMT activated an alternative methylated-intermediate pathway, raising camptothecin content in leaves and hairy roots. The resulting direction is optimization of camptothecin biosynthesis and yield, not improvement of its pharmacological delivery or antitumor action.

camptothecin chemical structure

Papers

The 15 papers from the last 6 months that study camptothecin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Targeted Camptothecin Delivery (15)
  1. Sanger's Reagent-Mediated Prodrug for Light-Controlled Release of Camptothecin With Fluorescent Indication. Chembiochem : a European journal of chemical biology · 28 Aug 2026 PMID 42661320
  2. Cabazitaxel and camptothecin co-loaded in pH-sensitive transferrin-targeted, PEGylated cholesterol-based poly(amidoamine) dendrimers as a synergistic combination for prostate cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 22 Jul 2026 PMID 42486016
  3. Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS nano · 21 Jul 2026 PMID 42478957
  4. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  5. Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
  6. Tumor-targeted activatable molecular agent for synergistic chemo-photodynamic therapy. Bioorganic chemistry · 3 Jul 2026 PMID 42398394
  7. Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
  8. Light-programmable, high-drug-loading nanomedicine based on dimeric camptothecin. Biomaterials science · 17 Jun 2026 PMID 42304791
  9. An HOCl-Activated Acyl Hydrazide Platform for Fluorescence-Guided Release of Hydroxyl-Containing Drugs. Analytical chemistry · 1 Jun 2026 PMID 42224648
  10. An HOCl-activated chemiluminescent prodrug enabling self-reporting camptothecin release and imaging-guided therapy in peritoneal metastasis. Bioorganic & medicinal chemistry · 29 May 2026 PMID 42214293
  11. A Tandem-Responsive and Multifunctional Dendritic Dot for Acid and γ-Glutamyl Transpeptidase-Activated Cancer Theranostics. Small (Weinheim an der Bergstrasse, Germany) · 17 May 2026 PMID 42143689
  12. Enhancing camptothecin biosynthesis in Camptotheca acuminata through CrLAMT transfer from Catharanthus roseus. Biotechnology letters · 15 May 2026 PMID 42138768
  13. γ-Glutamyl Transferase/Glutathione Cascade-Responsive Unimolecular Nanoprodrug for Precise Cancer Chemotherapy. Biomacromolecules · 2 May 2026 PMID 42068279
  14. Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy. Journal of medicinal chemistry · 30 Apr 2026 PMID 42059187
  15. Multifunctional niosome-chitosan-gold nanohybrids for pH/ROS-triggered camptothecin release in breast cancer treatment. Bioorganic chemistry · 16 Apr 2026 PMID 41990535

By study type

Preclinical: animal, cell and lab studies (15)
  1. Sanger's Reagent-Mediated Prodrug for Light-Controlled Release of Camptothecin With Fluorescent Indication. Chembiochem : a European journal of chemical biology · 28 Aug 2026 PMID 42661320
  2. Cabazitaxel and camptothecin co-loaded in pH-sensitive transferrin-targeted, PEGylated cholesterol-based poly(amidoamine) dendrimers as a synergistic combination for prostate cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 22 Jul 2026 PMID 42486016
  3. Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS nano · 21 Jul 2026 PMID 42478957
  4. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  5. Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
  6. Tumor-targeted activatable molecular agent for synergistic chemo-photodynamic therapy. Bioorganic chemistry · 3 Jul 2026 PMID 42398394
  7. Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
  8. Light-programmable, high-drug-loading nanomedicine based on dimeric camptothecin. Biomaterials science · 17 Jun 2026 PMID 42304791
  9. An HOCl-Activated Acyl Hydrazide Platform for Fluorescence-Guided Release of Hydroxyl-Containing Drugs. Analytical chemistry · 1 Jun 2026 PMID 42224648
  10. An HOCl-activated chemiluminescent prodrug enabling self-reporting camptothecin release and imaging-guided therapy in peritoneal metastasis. Bioorganic & medicinal chemistry · 29 May 2026 PMID 42214293
  11. A Tandem-Responsive and Multifunctional Dendritic Dot for Acid and γ-Glutamyl Transpeptidase-Activated Cancer Theranostics. Small (Weinheim an der Bergstrasse, Germany) · 17 May 2026 PMID 42143689
  12. Enhancing camptothecin biosynthesis in Camptotheca acuminata through CrLAMT transfer from Catharanthus roseus. Biotechnology letters · 15 May 2026 PMID 42138768
  13. γ-Glutamyl Transferase/Glutathione Cascade-Responsive Unimolecular Nanoprodrug for Precise Cancer Chemotherapy. Biomacromolecules · 2 May 2026 PMID 42068279
  14. Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy. Journal of medicinal chemistry · 30 Apr 2026 PMID 42059187
  15. Multifunctional niosome-chitosan-gold nanohybrids for pH/ROS-triggered camptothecin release in breast cancer treatment. Bioorganic chemistry · 16 Apr 2026 PMID 41990535